Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1/2 Study to Evaluate Novel Interleukin-18 Variant in Cancer
January 27, 2022 09:00 ET
|
Simcha Therapeutics, Inc.
Financing led by SR One; Proceeds to advance proprietary IL-18 variant through Phase 2 clinical trial ST-067 is a first-in-class "decoy resistant" IL-18 variant designed to overcome IL-18 binding in...
Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts
June 02, 2021 08:00 ET
|
Brooklyn ImmunoTherapeutics
BROOKLYN, N.Y., June 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and...